Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605). J of Skin [Internet]. 2026 Mar. 10 [cited 2026 Apr. 29];10(2):s746. Available from: https://skin.dermsquared.com/skin/article/view/4116